Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.

You may also be interested in...



U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails

The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.

Xarelto And Pradaxa Stumble At High U.K. Reimbursement Hurdles

NICE issues draft rejection of Bayer's blood thinner Xarelto for use in preventing stroke associated with atrial fibrillation, while a U.K. payer fights a positive recommendation for Boehringer Ingelheim's Pradaxa in the same indication.

U.K. Industry Promotes Real World Data As Backbone Of Value-Based Purchasing, Despite Government Lethargy

The U.K. government has sidelined the VBP debate, preferring to focus on other aspects of health care reform, but industry is pressing ahead with its vision for pricing and reimbursement evaluation.

Related Content

Topics

UsernamePublicRestriction

Register

PS072236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel